Year: 2021
Type: article
Abstract: Anxiety and stress-related conditions represent a significant health burden in modern society. Unfortunately, most anxiolytic drugs are prone to side effects, limiting their long-term usage. Here, we employ a bioinformatics screen to identify drugs for repurposing as anxiolytics. Comparison of drug-induced gene-expression profiles with the hippocampal transcriptome of an importin α5 mutant mouse model with reduced anxiety identifies the hypocholesterolemic agent β-sitosterol as a promising candidate. β-sitosterol activity is validated by both intraperitoneal and oral application in mice, revealing it as the only clear anxiolytic from five closely related phytosterols. β-sitosterol injection reduces the effects of restraint stress, contextual fear memory, and c-Fos activation in the prefrontal cortex and dentate gyrus. Moreover, synergistic anxiolysis is observed when combining sub-efficacious doses of β-sitosterol with the SSRI fluoxetine. These preclinical findings support further development of β-sitosterol, either as a standalone anxiolytic or in combination with low-dose SSRIs.
Source: Cell Reports Medicine
Institution: Weizmann Institute of Science
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $5,200
Funders: Weizmann Institute of Science, Ministry of Aliyah and Immigrant Absorption, Nella and Leon Benoziyo Center for Neurological Diseases, Weizmann Institute of Science, Carolito Stiftung, European Research Council, Feinberg Graduate School, Weizmann Institute of Science, H2020 European Research Council
Awards: G358642351, G6738281383
OpenAlex ID: W3160920105
